Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
taletrectinib + carboplatin + pemetrexed
- Development stage
- Unknown
- Lead developer
- Nuvation Bio
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy comprising **taletrectinib**, **carboplatin**, and **pemetrexed**. - **Taletrectinib** is a small molecule inhibitor of the tyrosine kinase domain of ROS1 and NTRK, being developed primarily for the treatment of ROS1-positive non-small cell lung cancer (NSCLC). Its mechanism involves selective inhibition of oncogenic ROS1 and NTRK kinases, blocking downstream signaling associated with tumor growth and survival. - **Carboplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking and strand breaks, leading to apoptosis in rapidly dividing tumor cells[3]. - **Pemetrexed** is an antifolate antineoplastic agent that inhibits several enzymes involved in folate metabolism and DNA synthesis, disrupting nucleotide synthesis and cell division[3]. This triple combination is under investigation for advanced or metastatic NSCLC with relevant oncogenic drivers.
02
Targets
ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)NTRK1 (Tropomyosin-related receptor kinase A)NTRK2 (Tropomyosin-related kinase receptor type B)NTRK3 (Tropomyosin receptor kinase C)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)TS (Thymidylate synthase)Trk (Trk receptor family)
Beyond the preview
Go deeper on taletrectinib + carboplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on taletrectinib + carboplatin + pemetrexed.